Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis.

Mice Female Humans Animals Antiviral Agents / pharmacology Plant Lectins Candidiasis, Vulvovaginal / drug therapy Disease Models, Animal Lectins / pharmacology HIV-1 Herpesvirus 2, Human Anti-Infective Agents, Local
Griffithsin Q-Griffithsin antifungal candidiasis lectins vaginal

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2022
Historique:
received: 22 06 2022
accepted: 30 09 2022
entrez: 4 11 2022
pubmed: 5 11 2022
medline: 8 11 2022
Statut: epublish

Résumé

Resistance to antifungal agents in vulvovaginal candidiasis has resulted in increasing morbidity among women globally. It is therefore crucial that new antimycotic agents are developed to counter this rising challenge. Q-Griffithsin (Q-GRFT) is a red algal lectin, manufactured in

Identifiants

DOI: 10.3389/fcimb.2022.976033 PMID: 36329822 PMC: PMC9623022
pubmed: 36329822
doi: 10.3389/fcimb.2022.976033
pmc: PMC9623022
doi:

Substances chimiques

q-griffithsin 0
Antiviral Agents 0
Plant Lectins 0
Lectins 0
Anti-Infective Agents, Local 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

976033

Subventions

Organisme : NHLBI NIH HHS
ID : U01 HL127518
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI113182
Pays : United States

Informations de copyright

Copyright © 2022 Nabeta, Lasnik, Fuqua, Wang, Rohan and Palmer.

Déclaration de conflit d'intérêts

The University of Louisville Research Foundation has filed patent applications claiming the use of Griffithsin in preventing and treating fungal infections. HN and KP are named as inventors. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Dev Immunol. 2011;2011:346307
pubmed: 21776285
Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):924-35
pubmed: 3895958
Sex Transm Dis. 2011 Jul;38(7):672-4
pubmed: 21844715
Antimicrob Agents Chemother. 2003 Jan;47(1):34-8
pubmed: 12499165
BMC Microbiol. 2018 Oct 25;18(1):166
pubmed: 30359236
Front Immunol. 2019 Aug 28;10:2034
pubmed: 31555269
Sci Rep. 2017 Dec 19;7(1):17877
pubmed: 29259175
Mycoses. 2015 Jun;58 Suppl 2:2-13
pubmed: 26033251
Biomolecules. 2019 Sep 23;9(10):
pubmed: 31547546
mBio. 2017 Mar 14;8(2):
pubmed: 28292981
Pharmaceutics. 2019 Apr 16;11(4):
pubmed: 30995761
Immunol Rev. 2005 Aug;206:306-35
pubmed: 16048557
Infect Immun. 2010 Dec;78(12):5126-37
pubmed: 20823201
Clin Infect Dis. 2013 Jun;56(12):1724-32
pubmed: 23487382
Antimicrob Agents Chemother. 2014;58(1):120-7
pubmed: 24145548
PLoS One. 2013 Dec 31;8(12):e83517
pubmed: 24391778
Braz J Microbiol. 2012 Apr;43(2):770-8
pubmed: 24031889
J Virol. 2010 Mar;84(5):2511-21
pubmed: 20032190
Clin Infect Dis. 2016 Feb 1;62(3):362-8
pubmed: 26486705
Viruses. 2016 Nov 17;8(11):
pubmed: 27869695
Front Microbiol. 2021 Jun 07;12:692491
pubmed: 34163460
J Infect Dis. 1996 Feb;173(2):425-31
pubmed: 8568305
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104
pubmed: 19332801
Infect Immun. 2004 May;72(5):2939-46
pubmed: 15102806
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5420-6
pubmed: 27381395
Viruses. 2016 Dec 17;8(12):
pubmed: 27999325
Cytokine. 2012 Apr;58(1):118-28
pubmed: 22182685
Sci Rep. 2018 May 23;8(1):8059
pubmed: 29795295
PLoS One. 2022 Jan 20;17(1):e0261775
pubmed: 35051209
PLoS Pathog. 2013;9(7):e1003486
pubmed: 23853597
Microbiol Spectr. 2021 Oct 31;9(2):e0095721
pubmed: 34494857
AAPS PharmSciTech. 2021 Feb 24;22(3):83
pubmed: 33625602
J Clin Invest. 2007 Dec;117(12):3664-72
pubmed: 17992260
Sci Rep. 2019 Dec 2;9(1):18120
pubmed: 31792342
J Virol. 2013 Jun;87(11):6257-69
pubmed: 23536670
J Control Release. 2020 May 10;321:84-99
pubmed: 32035194
Am J Obstet Gynecol. 2016 Jan;214(1):15-21
pubmed: 26164695
MMWR Surveill Summ. 2019 Sep 27;68(8):1-15
pubmed: 31557145
PLoS Pathog. 2014 Apr 03;10(4):e1003965
pubmed: 24699903
Nat Rev Immunol. 2015 Oct;15(10):630-42
pubmed: 26388329
PLoS One. 2011;6(8):e22635
pubmed: 21829638
PLoS One. 2012;7(9):e46311
pubmed: 23050010
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32229493
Antimicrob Agents Chemother. 2008 Sep;52(9):3022-8
pubmed: 18591269
Lancet Infect Dis. 2018 Nov;18(11):e339-e347
pubmed: 30078662
Int J Antimicrob Agents. 2017 Nov;50(5):599-606
pubmed: 28669835
Front Microbiol. 2019 Jul 02;10:1466
pubmed: 31333606
J Low Genit Tract Dis. 2011 Oct;15(4):263-7
pubmed: 21959570
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Virology. 2011 Sep 1;417(2):253-8
pubmed: 21802104
Nat Commun. 2018 Sep 24;9(1):3881
pubmed: 30250170
J Biol Chem. 2005 Mar 11;280(10):9345-53
pubmed: 15613479
Curr Opin HIV AIDS. 2016 Mar;11(2):156-62
pubmed: 26628324
Lancet. 2007 Jun 9;369(9577):1961-71
pubmed: 17560449
Mucosal Immunol. 2010 Jan;3(1):17-28
pubmed: 19890268
J Fungi (Basel). 2020 Feb 25;6(1):
pubmed: 32106438
J Infect Dis. 2020 May 11;221(Supplement_4):S480-S492
pubmed: 32037447
Curr Protoc Immunol. 2014 Apr 02;105:19.6.1-19.6.17
pubmed: 24700323
Infect Immun. 2014 Feb;82(2):532-43
pubmed: 24478069
Nat Rev Microbiol. 2008 Jan;6(1):67-78
pubmed: 18079743
J Dent Res. 2008 Oct;87(10):915-27
pubmed: 18809744
Mucosal Immunol. 2008 Nov;1(6):451-9
pubmed: 19079212
J Reprod Immunol. 2011 Mar;88(2):185-94
pubmed: 21353708

Auteurs

Henry W Nabeta (HW)

Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville KY, United States.
Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville KY, United States.

Amanda B Lasnik (AB)

Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville KY, United States.

Joshua L Fuqua (JL)

Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville KY, United States.
Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville KY, United States.

Lin Wang (L)

Infectious Diseases, Magee-Womens Research Institute, Pittsburgh, PA, United States.

Lisa C Rohan (LC)

Infectious Diseases, Magee-Womens Research Institute, Pittsburgh, PA, United States.
Department of Obstetrics, Gynecology, & Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA, United States.

Kenneth E Palmer (KE)

Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville KY, United States.
Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville KY, United States.
Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville KY, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Eucaryotes › Animaux › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines végétales › Lectines végétales › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Maladies urogénitales › Maladies génitales › Maladies de l'appareil génital féminin › Maladies de la vulve › Vulvite › Vulvovaginite › Candidose vulvovaginale › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lectines › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Virus › Virus à ADN › Herpesviridae › Alphaherpesvirinae › Simplexvirus › Herpèsvirus humain de type 2 › Antiviral lectin Q-Griffithsin suppresses...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Anti-infectieux locaux › Antiviral lectin Q-Griffithsin suppresses...